Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model (2016-003295-46)
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model (Colon-Resist-Net)
Sponsor: MGO Ruhr-University Bochum (RUB)
Listed as NCT03263663, this observational or N/A phase trial focuses on Colo-rectal Cancer and RAS Wild-type and remains ongoing. Sponsored by MGO Ruhr-University Bochum (RUB), it has been updated 9 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Feb 2025 — Present [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Dec 2021 — Jul 2024 [monthly]
Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
May 2018 — Nov 2020 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MGO Ruhr-University Bochum (RUB)
- PD Dr. med. Volker Heinemann
For direct contact, visit the study record on ClinicalTrials.gov .